Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. [electronic resource]
Producer: 20170904Description: 981-92 p. digitalISSN:- 1179-2027
- Antiviral Agents -- administration & dosage
- Carbamates
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Pyrrolidines
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Comparative Study; Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.